🚀 VC round data is live in beta, check it out!
DSM-Firmenich Valuation Multiples
Discover revenue and EBITDA valuation multiples for DSM-Firmenich and similar public comparables like SABIC Agri-Nutrient, Industries Qatar, Nippon Sanso Holdings, Nippon Paint and more.
DSM-Firmenich Overview
About DSM-Firmenich
DSM-Firmenich is a global science-based company formed in 2023 through the merger of DSM, a Dutch nutrition, health, and sustainable living player, and Switzerland-based Firmenich, the third-largest player in the flavor and fragrance market. The company serves a wide range of end-consumer markets providing nutrition solutions ranging from medical and early-life nutrition, fragrances for personal-, home-, and laundry-care brands, prestige perfumes, and other ingredients for food and beverage, home, and personal care. DSM-Firmenich has nearly 30,000 employees, with more than 2,000 scientists and engineers spread across 15 research and development facilities.
Founded
2022
HQ
Employees
27.0K
Website
Sectors
Financials (LTM)
EV
$21B
DSM-Firmenich Financials
DSM-Firmenich reported last 12-month revenue of $14B and EBITDA of $3B.
In the same LTM period, DSM-Firmenich generated $7B in gross profit, $3B in EBITDA, and $791M in net income.
Revenue (LTM)
DSM-Firmenich P&L
In the most recent fiscal year, DSM-Firmenich reported revenue of $15B and EBITDA of $4B.
DSM-Firmenich expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $14B | XXX | $15B | XXX | XXX | XXX |
| Gross Profit | $7B | XXX | $4B | XXX | XXX | XXX |
| Gross Margin | 52% | XXX | 27% | XXX | XXX | XXX |
| EBITDA | $3B | XXX | $4B | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 30% | XXX | XXX | XXX |
| EBIT Margin | 10% | XXX | 10% | XXX | XXX | XXX |
| Net Profit | $791M | XXX | $825M | XXX | XXX | XXX |
| Net Margin | 6% | XXX | 6% | XXX | XXX | XXX |
| Net Debt | — | — | $4B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
DSM-Firmenich Stock Performance
DSM-Firmenich has current market cap of $17B, and enterprise value of $21B.
Market Cap Evolution
DSM-Firmenich's stock price is $69.31.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $21B | $17B | 1.0% | XXX | XXX | XXX | $3.28 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDSM-Firmenich Valuation Multiples
DSM-Firmenich trades at 1.5x EV/Revenue multiple, and 8.3x EV/EBITDA.
EV / Revenue (LTM)
DSM-Firmenich Financial Valuation Multiples
As of April 2, 2026, DSM-Firmenich has market cap of $17B and EV of $21B.
Equity research analysts estimate DSM-Firmenich's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
DSM-Firmenich has a P/E ratio of 22.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $17B | XXX | $17B | XXX | XXX | XXX |
| EV (current) | $21B | XXX | $21B | XXX | XXX | XXX |
| EV/Revenue | 1.5x | XXX | 1.4x | XXX | XXX | XXX |
| EV/EBITDA | 8.3x | XXX | 4.8x | XXX | XXX | XXX |
| EV/EBIT | 15.2x | XXX | 13.7x | XXX | XXX | XXX |
| EV/Gross Profit | 3.0x | XXX | 5.2x | XXX | XXX | XXX |
| P/E | 22.0x | XXX | 21.1x | XXX | XXX | XXX |
| EV/FCF | 26.2x | XXX | 28.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified DSM-Firmenich Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
DSM-Firmenich Margins & Growth Rates
DSM-Firmenich's revenue in the last 12 month declined by (20%).
DSM-Firmenich's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.1M for the same period.
DSM-Firmenich's rule of 40 is 25% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
DSM-Firmenich's rule of X is 33% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
DSM-Firmenich Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (20%) | XXX | (26%) | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 30% | XXX | XXX | XXX |
| EBITDA Growth | (16%) | XXX | (52%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 25% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 33% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 10% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 7% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5% | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 23% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
DSM-Firmenich Public Comps
See public comps and valuation multiples for other Chemicals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| SABIC Agri-Nutrient | XXX | XXX | XXX | XXX | XXX | XXX |
| Industries Qatar | XXX | XXX | XXX | XXX | XXX | XXX |
| Nippon Sanso Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| Nippon Paint | XXX | XXX | XXX | XXX | XXX | XXX |
| LG Chem | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
DSM-Firmenich M&A Activity
DSM-Firmenich acquired XXX companies to date.
Last acquisition by DSM-Firmenich was on XXXXXXXX, XXXXX. DSM-Firmenich acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by DSM-Firmenich
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialDSM-Firmenich Investment Activity
DSM-Firmenich invested in XXX companies to date.
DSM-Firmenich made its latest investment on XXXXXXXX, XXXXX. DSM-Firmenich invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by DSM-Firmenich
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout DSM-Firmenich
| When was DSM-Firmenich founded? | DSM-Firmenich was founded in 2022. |
| Where is DSM-Firmenich headquartered? | DSM-Firmenich is headquartered in Switzerland. |
| How many employees does DSM-Firmenich have? | As of today, DSM-Firmenich has over 27K employees. |
| Is DSM-Firmenich publicly listed? | Yes, DSM-Firmenich is a public company listed on Euronext Amsterdam. |
| What is the stock symbol of DSM-Firmenich? | DSM-Firmenich trades under DSFIR ticker. |
| When did DSM-Firmenich go public? | DSM-Firmenich went public in 2023. |
| Who are competitors of DSM-Firmenich? | DSM-Firmenich main competitors are SABIC Agri-Nutrient, Industries Qatar, Nippon Sanso Holdings, Nippon Paint. |
| What is the current market cap of DSM-Firmenich? | DSM-Firmenich's current market cap is $17B. |
| What is the current revenue of DSM-Firmenich? | DSM-Firmenich's last 12 months revenue is $14B. |
| What is the current revenue growth of DSM-Firmenich? | DSM-Firmenich revenue growth (NTM/LTM) is (20%). |
| What is the current EV/Revenue multiple of DSM-Firmenich? | Current revenue multiple of DSM-Firmenich is 1.5x. |
| Is DSM-Firmenich profitable? | Yes, DSM-Firmenich is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of DSM-Firmenich? | DSM-Firmenich's last 12 months EBITDA is $3B. |
| What is DSM-Firmenich's EBITDA margin? | DSM-Firmenich's last 12 months EBITDA margin is 18%. |
| What is the current EV/EBITDA multiple of DSM-Firmenich? | Current EBITDA multiple of DSM-Firmenich is 8.3x. |
| What is the current FCF of DSM-Firmenich? | DSM-Firmenich's last 12 months FCF is $814M. |
| What is DSM-Firmenich's FCF margin? | DSM-Firmenich's last 12 months FCF margin is 6%. |
| What is the current EV/FCF multiple of DSM-Firmenich? | Current FCF multiple of DSM-Firmenich is 26.2x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.